Dipyridopyrazine Integrase Inhibitors for HIV Drug Interaction Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapies for HIV infection require multiple drugs, leading to potential drug interactions and resistance, necessitating the development of new agents that inhibit HIV replication with minimal drug-drug interactions.
Innovation Solution
Novel polycyclic carbamoylpyridone compounds with antiviral activity, including stereoisomers and pharmaceutically acceptable salts, are developed to inhibit HIV integrase and reduce replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple drugs are used for HIV treatment, then viral suppression is achieved, but drug interactions and resistance increase
Solution Approach 1:
The patent combines multiple therapeutic functions into a single integrase inhibitor compound. The compound of Formula (I) is designed to inhibit HIV integrase while also possessing antiviral properties, thereby achieving viral suppression through one agent rather than multiple drugs, thus reducing drug interactions
Solution Approach 2:
The integrase inhibitor compound serves multiple functions: it inhibits HIV integrase enzyme activity, prevents viral integration into host DNA, and exhibits broad antiviral activity. This multi-functionality allows a single compound to address multiple aspects of HIV pathogenesis that previously required separate medications
2Reliability
If multiple drugs are used for HIV treatment, then viral suppression is achieved, but development of resistant strains increases
Solution Approach 1:
By merging integrase inhibition and antiviral activities into one compound, the patent reduces the selective pressure and metabolic pathways that lead to resistance. The compound targets integrase with high specificity while its antiviral properties provide an additional mechanism of action that makes resistance less likely to develop
Solution Approach 2:
The patent optimizes the chemical structure of the integrase inhibitor (Formula I) to achieve optimal binding affinity and selectivity. By carefully adjusting molecular parameters such as substituent groups Y1, Y2, R1, and the linker L, the compound achieves potent integrase inhibition with minimal off-target effects, reducing the likelihood of resistance development
3Adaptability or versatility
If multiple drugs are used for HIV treatment, then comprehensive coverage is achieved, but complexity of treatment increases
Solution Approach 1:
The integrase inhibitor compound provides comprehensive HIV treatment coverage through its dual mechanism of integrase inhibition and antiviral activity. This single multi-functional agent replaces multiple separate medications, simplifying the treatment regimen while maintaining broad therapeutic coverage
Solution Approach 2:
The compound is designed with specific structural segments (Y1, Y2, R1 substituents, and L linker) that can be independently optimized to target different aspects of HIV pathogenesis. This modular design allows the single compound to address multiple therapeutic needs without requiring multiple separate drugs
4Productivity
If standard combination therapy is used, then HIV replication is suppressed, but potential for drug interactions increases
Solution Approach 1:
The patent merges integrase inhibition and antiviral functions into one compound, eliminating the need for combination therapy with multiple drugs. This single agent achieves HIV replication suppression without the drug-drug interactions that occur when multiple medications are administered together
Solution Approach 2:
The integrase inhibitor compound is designed to be self-sufficient, providing both integrase inhibition and antiviral activities within a single molecular entity. This self-service capability eliminates the need for external combination therapies and their associated interaction risks
Data Source
AI summary
Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I):including stereoisomers and pharmaceutically acceptable salts thereof, wherein L, R1, R5, W, X, Y1, Y2, and Z are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.